Atg3 Inhibitors

Atg3, a key player in the autophagy process, is primarily involved in the LC3 lipidation, an essential step in autophagosome formation. Inhibitors targeting Atg3, both directly and indirectly, are significant in understanding and modulating autophagy. Autophagy, a cellular degradation and recycling process, is crucial for cell survival, differentiation, development, and homeostasis. It plays a pivotal role in various diseases, including cancer, neurodegeneration, and infections.

Direct inhibitors of Atg3 are scarce, as Atg3's specific mechanism of action in the E2-like enzyme activity presents challenges in direct targeting. However, compounds like Spautin-1 demonstrate indirect inhibition by affecting proteins that influence Atg3's function, such as USP10 and USP13, which regulate the ubiquitination and stability of key autophagy proteins. Verteporfin, another indirect inhibitor, disrupts autophagosome formation by targeting the YAP-TEAD complex, thus influencing the expression of autophagy-related genes. The majority of Atg3 inhibitors function by modulating the autophagy pathway indirectly. Agents like Chloroquine and Hydroxychloroquine inhibit the final stages of autophagy, affecting autophagosome-lysosome fusion, indirectly impacting Atg3's role in autophagosome maturation. PI3K inhibitors such as 3-MA, SAR405, Wortmannin, and LY294002 target the initiation stage of autophagy, thus indirectly influencing Atg3's activity. The mTOR pathway, a central regulator of autophagy, is another target for indirect inhibition of Atg3. mTOR inhibitors like Torin 1 and AZD8055 promote autophagy, thereby affecting Atg3's functional context, while MHY1485, an mTOR activator, inhibits autophagy, offering an alternate approach to modulate Atg3's activity.